what's the difference between compounded semaglutide and semaglutide Some Pharmacies Are Offering Unauthorized Ozempic Alternatives FDA Warns on Certain Forms

Our latest study explores how the proliferation of GLP-1 therapies is influencing, and potentially replacing, treatment patterns for legacy #obesity products and changing the approach to #weightmanagement writ large GLP-1 therapies drive growth in anti-obesity treatments From 2018 to 2021, patient volume for anti-obesity therapies increased by 16.4%, compared to 94.5% from 2021 to 2024, following the approvals of #Wegovy in June 2021 and #Zepbound in November 2023

Annu Rev Physiol 59:257271

Importantly, these improvements were achieved with a low risk of hypoglycemia and increased treatment satisfaction

However, direct evidence for true synaptic rescue remains limited

It is important to note that fatigue is often multifactorial, influenced by the underlying condition being treated, lifestyle factors, or concurrent medications